Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Biospecimen User Fees: Global Feedback on a Calculator Tool.

Matzke LA, Babinszky S, Slotty A, Meredith A, Castillo-Pelayo T, Henderson MK, Simeon-Dubach D, Schacter B, Watson PH.

Biopreserv Biobank. 2017 Feb;15(1):57-64. doi: 10.1089/bio.2016.0027. Epub 2016 Aug 30.

2.

A practical tool for modeling biospecimen user fees.

Matzke L, Dee S, Bartlett J, Damaraju S, Graham K, Johnston R, Mes-Masson AM, Murphy L, Shepherd L, Schacter B, Watson PH.

Biopreserv Biobank. 2014 Aug;12(4):234-9. doi: 10.1089/bio.2014.0008.

PMID:
25162459
3.

The Biobank Economic Modeling Tool (BEMT): Online Financial Planning to Facilitate Biobank Sustainability.

Odeh H, Miranda L, Rao A, Vaught J, Greenman H, McLean J, Reed D, Memon S, Fombonne B, Guan P, Moore HM.

Biopreserv Biobank. 2015 Dec;13(6):421-9. doi: 10.1089/bio.2015.0089.

4.

Funding sources for Canadian biorepositories: the role of user fees and strategies to help fill the gap.

Barnes RO, Schacter B, Kodeeswaran S; CTRNet Management Committee, Watson PH.

Biopreserv Biobank. 2014 Oct;12(5):300-5. doi: 10.1089/bio.2014.0052. Epub 2014 Oct 14.

PMID:
25314324
5.

Certification for biobanks: the program developed by the Canadian Tumour Repository Network (CTRNet).

Matzke EA, O'Donoghue S, Barnes RO, Daudt H, Cheah S, Suggitt A, Bartlett J, Damaraju S, Johnston R, Murphy L, Shepherd L, Mes-Masson AM, Schacter B, Watson PH.

Biopreserv Biobank. 2012 Oct;10(5):426-32. doi: 10.1089/bio.2012.0026.

PMID:
24845043
6.

Biobank classification in an Australian setting.

Rush A, Christiansen JH, Farrell JP, Goode SM, Scott RJ, Spring KJ, Byrne JA.

Biopreserv Biobank. 2015 Jun;13(3):212-8. doi: 10.1089/bio.2015.0007.

PMID:
26035012
7.

The Future of Biobanking: A Conceptual Look at How Biobanks Can Respond to the Growing Human Biospecimen Needs of Researchers.

Somiari SB, Somiari RI.

Adv Exp Med Biol. 2015;864:11-27. doi: 10.1007/978-3-319-20579-3_2. Review.

PMID:
26420610
8.

Challenges and Driving Forces for Business Plans in Biobanking.

Macheiner T, Huppertz B, Bayer M, Sargsyan K.

Biopreserv Biobank. 2017 Apr;15(2):121-125. doi: 10.1089/bio.2017.0018. Epub 2017 Mar 24.

PMID:
28338345
9.

Biobank bootstrapping: is biobank sustainability possible through cost recovery?

Albert M, Bartlett J, Johnston RN, Schacter B, Watson P.

Biopreserv Biobank. 2014 Dec;12(6):374-80. doi: 10.1089/bio.2014.0051.

PMID:
25496148
10.

A Model to Estimate Frozen Tissue Collection Targets in Biobanks to Support Cancer Research.

Meredith AJ, Slotty A, Matzke L, Babinszky S, Watson PH.

Biopreserv Biobank. 2015 Oct;13(5):356-62. doi: 10.1089/bio.2014.0081. Epub 2015 Sep 29.

PMID:
26418967
11.

[Current modalities and concepts on access and use of biospecimen samples and associated data for research from human biobanks].

Siddiqui R, Semler SC.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Mar;59(3):317-24. doi: 10.1007/s00103-015-2293-4. German.

PMID:
26809822
12.

Evolutionary concepts in biobanking - the BC BioLibrary.

Watson PH, Wilson-McManus JE, Barnes RO, Giesz SC, Png A, Hegele RG, Brinkman JN, Mackenzie IR, Huntsman DG, Junker A, Gilks B, Skarsgard E, Burgess M, Aparicio S, McManus BM.

J Transl Med. 2009 Nov 12;7:95. doi: 10.1186/1479-5876-7-95.

13.

Economic Impacts of the Generic Drug User Fee Act Fee Structure.

Dong K, Boehm G, Zheng Q.

Value Health. 2017 Jun;20(6):792-798. doi: 10.1016/j.jval.2016.05.003. Epub 2016 Jul 15.

14.
15.

Sustainability in Biobanking: Model of Biobank Graz.

Sargsyan K, Macheiner T, Story P, Strahlhofer-Augsten M, Plattner K, Riegler S, Granitz G, Bayer M, Huppertz B.

Biopreserv Biobank. 2015 Dec;13(6):410-20. doi: 10.1089/bio.2015.0087.

PMID:
26697910
16.

Generating a comprehensive set of standard operating procedures for a biorepository network-The CTRNet experience.

Barnes R, Albert M, Damaraju S, de Sousa-Hitzler J, Kodeeswaran S, Mes-Masson AM, Watson P, Schacter B.

Biopreserv Biobank. 2013 Dec;11(6):387-96. doi: 10.1089/bio.2013.0061. Epub 2013 Nov 22.

PMID:
24835369
17.

The challenge of sustaining a hospital-based biobank and core molecular laboratory: the Beaumont experience.

Wilson GD, D'Angelo K, Pruetz BL, Geddes TJ, Larson DM, Akervall J.

Biopreserv Biobank. 2014 Oct;12(5):306-11. doi: 10.1089/bio.2014.0049. Epub 2014 Oct 14.

PMID:
25314610
18.

Critical Financial Challenges for Biobanking: Report of a National Cancer Institute Study.

Rao A, Vaught J, Tulskie B, Olson D, Odeh H, McLean J, Moore HM.

Biopreserv Biobank. 2019 Apr;17(2):129-138. doi: 10.1089/bio.2018.0069. Epub 2019 Jan 14.

PMID:
30638412
19.

Market-driven production of biospecimens and the role of NHS hospital-led biobanks.

Timmons S, Vezyridis P.

Sociol Health Illn. 2017 Sep;39(7):1242-1257. doi: 10.1111/1467-9566.12584. Epub 2017 May 27.

PMID:
28555937
20.

Construction of a business model to assure financial sustainability of biobanks.

Warth R, Perren A.

Biopreserv Biobank. 2014 Dec;12(6):389-94. doi: 10.1089/bio.2014.0057.

PMID:
25496150

Supplemental Content

Support Center